JPWO2019147973A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019147973A5 JPWO2019147973A5 JP2020561607A JP2020561607A JPWO2019147973A5 JP WO2019147973 A5 JPWO2019147973 A5 JP WO2019147973A5 JP 2020561607 A JP2020561607 A JP 2020561607A JP 2020561607 A JP2020561607 A JP 2020561607A JP WO2019147973 A5 JPWO2019147973 A5 JP WO2019147973A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid position
- tyrosine
- binding polypeptide
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 claims 121
- 150000001413 amino acids Chemical group 0.000 claims 121
- 229920001184 polypeptide Polymers 0.000 claims 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims 54
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 44
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 44
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 20
- 235000003704 aspartic acid Nutrition 0.000 claims 19
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 19
- 238000006467 substitution reaction Methods 0.000 claims 14
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 13
- 230000002378 acidificating effect Effects 0.000 claims 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 12
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 11
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 8
- 235000013922 glutamic acid Nutrition 0.000 claims 8
- 239000004220 glutamic acid Substances 0.000 claims 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 7
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 6
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 1
- 229930010555 Inosine Natural products 0.000 claims 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101000913100 Rattus norvegicus IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003786 inosine Drugs 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Claims (40)
アミノ酸位置434にフェニルアラニン(F)若しくはチロシン(Y);又は
アミノ酸位置252にチロシン(Y)を含み、
ただし、アミノ酸位置252にチロシン(Y)及びアミノ酸位置256にグルタミン酸(E)を含む場合は、アミノ酸位置254にスレオニン(T)は含まず、
ここでアミノ酸位置はEUナンバリングに従う、
改変されたFcドメインを含む単離された結合ポリペプチド。 Amino acid position 256 contains aspartic acid (D) or glutamic acid (E), and / or amino acid position 307 contains tryptophan (W) or glutamine (Q), and further:
Amino acid position 434 contains phenylalanine (F) or tyrosine (Y); or amino acid position 252 contains tyrosine (Y).
However, when tyrosine (Y) is contained at the amino acid position 252 and glutamic acid (E) is contained at the amino acid position 256, threonine (T) is not contained at the amino acid position 254.
Here the amino acid positions follow EU numbering,
An isolated binding polypeptide containing a modified Fc domain.
b)アミノ酸位置256のアスパラギン酸(D)、及びアミノ酸位置434のフェニルアラニン(F);
c)アミノ酸位置256のアスパラギン酸(D)、及びアミノ酸位置434のチロシン(Y);
d)アミノ酸位置307のトリプトファン(W)、及びアミノ酸位置434のフェニルアラニン(F);
e)アミノ酸位置252のチロシン(Y)、及びアミノ酸位置307のトリプトファン(W)、ここでチロシン(Y)はアミノ酸位置434に存在しない;
f)アミノ酸位置256のアスパラギン酸(D)、及びアミノ酸位置307のトリプトファン(W)、ここでチロシン(Y)はアミノ酸位置434に存在しない;
g)アミノ酸位置256のアスパラギン酸(D)、及びアミノ酸位置307のグルタミン(Q)、ここでチロシン(Y)はアミノ酸位置434に存在しない;
h)アミノ酸位置252のチロシン(Y)、アミノ酸位置256のアスパラギン酸(D)、及びアミノ酸位置307のグルタミン(Q)、ここでチロシン(Y)はアミノ酸位置434に存在しない;並びに
i)アミノ酸位置252のチロシン(Y)、アミノ酸位置256のグルタミン酸(E)、及びアミノ酸位置307のグルタミン(Q)、ここでスレオニン(T)はアミノ酸位置254に存在せず、ヒスチジン(H)はアミノ酸位置311に存在せず、そしてチロシン(Y)はアミノ酸位置434に存在しない;
からなる群より選択される位置のアミノ酸置換の組み合わせを含み、
ここで、アミノ酸置換はEUナンバリングに従う、
改変されたFcドメインを含む単離された結合ポリペプチド。 a) Tyrosine (Y) at amino acid position 252 and aspartic acid (D) at amino acid position 256;
b) Aspartic acid (D) at amino acid position 256 and phenylalanine (F) at amino acid position 434;
c) Aspartic acid (D) at amino acid position 256 and tyrosine (Y) at amino acid position 434;
d) Tryptophan (W) at amino acid position 307 and phenylalanine (F) at amino acid position 434;
e) Tyrosine (Y) at amino acid position 252 and tryptophan (W) at amino acid position 307, where tyrosine (Y) is absent at amino acid position 434;
f) Aspartic acid (D) at amino acid position 256, and tryptophan (W) at amino acid position 307, where tyrosine (Y) is absent at amino acid position 434;
g) Aspartic acid (D) at amino acid position 256, and glutamine (Q) at amino acid position 307, where tyrosine (Y) is absent at amino acid position 434;
h) Tyrosine (Y) at amino acid position 252, aspartic acid (D) at amino acid position 256, and glutamine (Q) at amino acid position 307, where tyrosine (Y) is absent at amino acid position 434; and i) amino acid position. Tyrosine (Y) at 252, glutamic acid (E) at amino acid position 256, and glutamine (Q) at amino acid position 307, where threonine (T) is absent at amino acid position 254 and histidine (H) is at amino acid position 311. Not present, and tyrosine (Y) is absent at amino acid position 434;
Contains a combination of amino acid substitutions at positions selected from the group consisting of
Here, amino acid substitutions follow EU numbering,
An isolated binding polypeptide containing a modified Fc domain.
b)M252Y/T256D/T307Q、M252Y/T256D/T307W、M252Y/T256E/T307Q、及びM252Y/T256E/T307Wからなる群より選択される三重アミノ酸置換、ここで、スレオニン(T)はアミノ酸位置254に存在せず、ヒスチジン(H)はアミノ酸位置311に存在せず、そしてチロシン(Y)はアミノ酸位置434に存在しない;
を含み、ここで、アミノ酸置換はEUナンバリングに従う、
改変されたFcドメインを含む単離された結合ポリペプチド。 a) A double amino acid substitution selected from the group consisting of M252Y / T256D, M252Y / T256E, M252Y / T307Q, M252Y / T307W, T256D / T307Q, T256D / T307W, T256E / T307Q, and T256E / T307W. (T) is not present at amino acid position 254, histidine (H) is not present at amino acid position 311, and tyrosine (Y) is not present at amino acid position 434; or b) M252Y / T256D / T307Q, M252Y / T256D. A triple amino acid substitution selected from the group consisting of / T307W, M252Y / T256E / T307Q, and M252Y / T256E / T307W, where threonine (T) is not present at amino acid position 254 and histidine (H) is at amino acid position 311. Not present in, and tyrosine (Y) is absent at amino acid position 434;
Containing, where amino acid substitutions follow EU numbering,
An isolated binding polypeptide containing a modified Fc domain.
アミノ酸位置252にチロシン(Y)、
アミノ酸位置256にアスパラギン酸(D)又はグルタミン酸(E)、
アミノ酸位置307にトリプトファン(W)又はグルタミン(Q)、及び
アミノ酸位置434にフェニルアラニン(F)又はチロシン(Y)
を含み、ここでアミノ酸位置はEUナンバリングに従う、
上記単離された結合ポリペプチド。 An isolated binding polypeptide containing a modified Fc domain, wherein the modified Fc domain is:
Tyrosine (Y) at amino acid position 252,
Aspartic acid (D) or glutamic acid (E) at amino acid position 256,
Tryptophan (W) or glutamine (Q) at amino acid position 307, and phenylalanine (F) or tyrosine (Y) at amino acid position 434.
Containing, where amino acid positions follow EU numbering,
The isolated binding polypeptide.
b)アミノ酸位置252のチロシン(Y)、アミノ酸位置256のグルタミン酸(E)、アミノ酸位置307のトリプトファン(W)、及びアミノ酸位置434のチロシン(Y);
c)アミノ酸位置252のチロシン(Y)、アミノ酸位置256のグルタミン酸(E)、アミノ酸位置307のグルタミン(Q)、及びアミノ酸位置434のチロシン(Y);
d)アミノ酸位置252のチロシン(Y)、アミノ酸位置256のアスパラギン酸(D)、アミノ酸位置307のグルタミン(Q)、及びアミノ酸位置434のフェニルアラニン(F);
e)アミノ酸位置252のチロシン(Y)、アミノ酸位置256のアスパラギン酸(D)、アミノ酸位置307のトリプトファン(W)、及びアミノ酸位置434のチロシン(Y);並びに
f)アミノ酸位置252のチロシン(Y)、アミノ酸位置256のアスパラギン酸(D)、アミノ酸位置307のトリプトファン(W)、及びアミノ酸位置434のフェニルアラニン(F);
からなる群より選択される位置のアミノ酸置換の組み合わせを含み、
ここでアミノ酸置換はEUナンバリングに従う、
改変されたFcドメインを含む単離された結合ポリペプチド。 a) Tyrosine (Y) at amino acid position 252, aspartic acid (D) at amino acid position 256, glutamine (Q) at amino acid position 307, and tyrosine (Y) at amino acid position 434;
b) Tyrosine (Y) at amino acid position 252, glutamic acid (E) at amino acid position 256, tryptophan (W) at amino acid position 307, and tyrosine (Y) at amino acid position 434;
c) Tyrosine (Y) at amino acid position 252, glutamic acid (E) at amino acid position 256, glutamine (Q) at amino acid position 307, and tyrosine (Y) at amino acid position 434;
d) Tyrosine (Y) at amino acid position 252, aspartic acid (D) at amino acid position 256, glutamine (Q) at amino acid position 307, and phenylalanine (F) at amino acid position 434;
e) Tyrosine (Y) at amino acid position 252, aspartic acid (D) at amino acid position 256, tryptophan (W) at amino acid position 307, and tyrosine (Y) at amino acid position 434; and f) tyrosine (Y) at amino acid position 252. ), Asparaginic acid (D) at amino acid position 256, tryptophan (W) at amino acid position 307, and phenylalanine (F) at amino acid position 434;
Contains a combination of amino acid substitutions at positions selected from the group consisting of
Here amino acid substitutions follow EU numbering,
An isolated binding polypeptide containing a modified Fc domain.
M252Y/T256E/T307W/N434Y、
M252Y/T256E/T307Q/N434Y、
M252Y/T256D/T307Q/N434F、
M252Y/T256D/T307W/N434Y、及び
M252Y/T256D/T307W/N434F
からなる群より選択される四重アミノ酸置換を含み、
ここでアミノ酸置換はEUナンバリングに従う、
改変されたFcドメインを含む単離された結合ポリペプチド。 M252Y / T256D / T307Q / N434Y,
M252Y / T256E / T307W / N434Y,
M252Y / T256E / T307Q / N434Y,
M252Y / T256D / T307Q / N434F,
M252Y / T256D / T307W / N434Y and M252Y / T256D / T307W / N434F
Containing quadruple amino acid substitutions selected from the group consisting of
Here amino acid substitutions follow EU numbering,
An isolated binding polypeptide containing a modified Fc domain.
b)アミノ酸位置252のチロシン(Y)、アミノ酸位置307のトリプトファン(W)、及びアミノ酸位置434のチロシン(Y);
c)アミノ酸位置252のチロシン(Y)、アミノ酸位置256のアスパラギン酸(D)、及びアミノ酸位置434のチロシン(Y); 又は
d)アミノ酸位置256のアスパラギン酸(D)、アミノ酸位置307のトリプトファン(W)、及びアミノ酸位置434のチロシン(Y);
を含み、ここでアミノ酸置換はEUナンバリングに従う、
改変されたFcドメインを含む単離された結合ポリペプチド。 a) Tyrosine (Y) at amino acid position 252 and tyrosine (Y) at amino acid position 434;
b) Tyrosine (Y) at amino acid position 252, tryptophan (W) at amino acid position 307, and tyrosine (Y) at amino acid position 434;
c) Tyrosine (Y) at amino acid position 252, aspartic acid (D) at amino acid position 256, and tyrosine (Y) at amino acid position 434; or d) Aspartic acid (D) at amino acid position 256, tryptophan at amino acid position 307 ( W), and tyrosine (Y) at amino acid position 434;
Containing, where amino acid substitutions follow EU numbering,
An isolated binding polypeptide containing a modified Fc domain.
M252Y/T307W/N434Y、
M252Y/T256D/N434Y、及び
T256D/T307W/N434Y
からなる群より選択されるアミノ酸置換の組み合わせを含み、
ここでアミノ酸置換はEUナンバリングに従う、
改変されたFcドメインを含む単離された結合ポリペプチド。 M252Y / N434Y,
M252Y / T307W / N434Y,
M252Y / T256D / N434Y and T256D / T307W / N434Y
Contains a combination of amino acid substitutions selected from the group consisting of
Here amino acid substitutions follow EU numbering,
An isolated binding polypeptide containing a modified Fc domain.
結合ポリペプチドを、培養物から分離する工程
を含む、単離された結合ポリペプチドを製造する方法。 Producing an isolated bound polypeptide comprising the step of culturing the host cell according to claim 35 under conditions that allow the expression of the bound polypeptide and the step of separating the bound polypeptide from the culture. how to.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023204313A JP2024026255A (en) | 2018-01-26 | 2023-12-04 | Fc variant with enhanced binding to fcrn and prolonged half-life |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862622468P | 2018-01-26 | 2018-01-26 | |
US62/622,468 | 2018-01-26 | ||
PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023204313A Division JP2024026255A (en) | 2018-01-26 | 2023-12-04 | Fc variant with enhanced binding to fcrn and prolonged half-life |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021511830A JP2021511830A (en) | 2021-05-13 |
JPWO2019147973A5 true JPWO2019147973A5 (en) | 2022-02-01 |
JP7399880B2 JP7399880B2 (en) | 2023-12-18 |
Family
ID=65520379
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020561607A Active JP7399880B2 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to FcRn and extended half-life |
JP2023204313A Pending JP2024026255A (en) | 2018-01-26 | 2023-12-04 | Fc variant with enhanced binding to fcrn and prolonged half-life |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023204313A Pending JP2024026255A (en) | 2018-01-26 | 2023-12-04 | Fc variant with enhanced binding to fcrn and prolonged half-life |
Country Status (15)
Country | Link |
---|---|
US (1) | US20190263934A1 (en) |
EP (1) | EP3743441A1 (en) |
JP (2) | JP7399880B2 (en) |
KR (1) | KR20200115568A (en) |
CN (1) | CN111788221A (en) |
AU (1) | AU2019212638A1 (en) |
BR (1) | BR112020015006A2 (en) |
CA (1) | CA3089602A1 (en) |
CO (1) | CO2020010269A2 (en) |
IL (1) | IL276286A (en) |
MX (1) | MX2020007882A (en) |
PH (1) | PH12020551134A1 (en) |
SG (1) | SG11202006905YA (en) |
TW (1) | TW201940512A (en) |
WO (1) | WO2019147973A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3148764A1 (en) * | 2019-07-25 | 2021-01-28 | Genzyme Corporation | Methods of treating antibody-mediated disorders with fcrn antagonists |
US11434276B2 (en) * | 2020-05-11 | 2022-09-06 | Invetx, Inc. | Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use |
JP2023547239A (en) * | 2020-10-29 | 2023-11-09 | フォーマイコン アーゲー | ACE2 fusion protein and method of use thereof |
BR112023022584A2 (en) | 2021-05-27 | 2024-01-09 | Sanofi Sa | FC VARIANT WITH INTENSIFIED AFFINITY WITH FC RECEPTORS AND IMPROVED THERMAL STABILITY |
EP4388004A1 (en) | 2021-08-20 | 2024-06-26 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
WO2023064856A1 (en) * | 2021-10-13 | 2023-04-20 | The Wistar Institute Of Anatomy And Biology | In vivo interacting protein domains and methods of use thereof |
WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
US20240166750A1 (en) | 2022-10-25 | 2024-05-23 | Ablynx N.V. | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION |
WO2024121755A1 (en) | 2022-12-05 | 2024-06-13 | Sanofi | Transferrin receptor binding proteins |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69232604T2 (en) | 1992-11-04 | 2002-11-07 | City Of Hope Duarte | ANTIBODY CONSTRUCTS |
US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
KR100940380B1 (en) * | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | Polypeptide Variants with Altered Effector Function |
CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
KR20080080675A (en) * | 2004-08-19 | 2008-09-04 | 제넨테크, 인크. | Polypeptide variants with altered effector function |
KR101027427B1 (en) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | Fc VARIANTS WITH INCREASED BINDING TO FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1896503B1 (en) * | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
WO2010068722A1 (en) * | 2008-12-12 | 2010-06-17 | Medimmune, Llc | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
DK2516468T3 (en) * | 2009-12-23 | 2016-05-23 | Synimmune Gmbh | ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE |
WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
TWI622597B (en) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | Dual variable region antibody-like binding proteins having cross-over binding region orientation |
GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
JP6322411B2 (en) * | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities |
US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
EP2992010B1 (en) * | 2013-04-29 | 2021-03-24 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
WO2016071376A2 (en) * | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
JP6787888B2 (en) | 2014-11-10 | 2020-11-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Anti-IL-1 beta antibody and usage |
-
2019
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en unknown
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 TW TW108102958A patent/TW201940512A/en unknown
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/en unknown
- 2019-01-25 AU AU2019212638A patent/AU2019212638A1/en active Pending
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 CN CN201980015900.4A patent/CN111788221A/en active Pending
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/en active Active
- 2019-01-25 KR KR1020207024432A patent/KR20200115568A/en not_active Application Discontinuation
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/en unknown
-
2020
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-07-26 IL IL276286A patent/IL276286A/en unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/en unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108350048B (en) | Constructs with SIRP-alpha domains or variants thereof | |
KR102247704B1 (en) | Anti-PD-1/anti-HER2 natural antibody structure-type heterodimeric bispecific antibody and its preparation method | |
CN110382529B (en) | Engineered heterodimeric proteins | |
TWI320788B (en) | Method for the purification of antibodies | |
JP7264383B2 (en) | Antibody Fc variants for improved serum half-life | |
JPWO2020116560A1 (en) | Fc region variant of antibody | |
US11945839B2 (en) | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography | |
JP7050838B2 (en) | Methods for selecting antibodies with altered FcRn interactions | |
TW201716442A (en) | Anti-EphA4 antibody | |
WO2022166728A1 (en) | Bispecific antibody | |
WO2021041250A1 (en) | Igm glycovariants | |
JP2023027215A (en) | Polypeptide linker for preparing multispecific antibody | |
JPWO2019147973A5 (en) | ||
JP2023544211A (en) | Polypeptides targeting SARS-COV-2 and related compositions and methods | |
WO2023072217A1 (en) | Fusion proteins targeting cd3 and cd47 | |
JPWO2015050153A1 (en) | A protein comprising a plurality of domains having an affinity for a protein having an Fc portion of immunoglobulin G (IgG) and linked by a linker. | |
JP2021528435A (en) | A method for producing a controlled mixture of two or more different antibodies | |
CN116917339A (en) | Polypeptides targeting DR4 and/or DR5 and related compositions and methods | |
WO2021003739A1 (en) | Tetravalent symmetric bispecific antibody | |
JP2015019615A (en) | Novel modified protein derived from variant of outer membrane domain of cell of protein g | |
RU2020128177A (en) | FC OPTIONS WITH INCREASED FCRN BINDING AND LONG HALF-LIFE | |
WO2021251438A1 (en) | Fusion protein containing erythropoietin polypeptide | |
JP2015003872A (en) | Purification method of mouse igg | |
WO2022045276A1 (en) | Heterodimer fc polypeptide | |
WO2022117065A1 (en) | Multispecific antigen binding protein |